Increasing investment – SCHOTT to double its manufacturing capacity for pharmaceutical glass tubing in China
11 November 2021, Jinyun, China
- A 70 million Euro investment will expand the melting infrastructure in Jinyun once again to meet the ever-growing demand for high-quality glass tubing for primary pharmaceutical packaging
- The groundbreaking for the new melting tanks will take place in early 2022
- FIOLAX® borosilicate glass is the gold standard for pharmaceutical packaging that safely stores COVID-19 vaccines and other drugs
Specialty glass tubing to manufacture pharma containers for drugs and vaccines requires special skills in melting and processing. FIOLAX® is highly inert and protects sensitive drugs from unwanted drug-container interactions. The material is a 5.0 Type I middle borosilicate glass and supports the strategy of the Chinese government to move away from the low borosilicate glass (7.0 glass).
Trademarks: FIOLAX® is a registered trademark from SCHOTT
Pioneering – responsibly – togetherThese attributes characterize SCHOTT as a manufacturer of high-tech materials based on specialty glass. Founder Otto Schott is considered its inventor and became the pioneer of an entire industry. Always opening up new markets and applications with a pioneering spirit and passion – this is what has driven the #glasslovers at SCHOTT for more than 130 years. Represented in 34 countries, the company is a highly skilled partner for high-tech industries: Healthcare, Home Appliances & Living, Consumer Electronics, Semiconductors & Datacom, Optics, Industry & Energy, Automotive, Astronomy, and Aerospace. In the fiscal year 2020, its 16,500 employees generated sales of 2.24 billion euros. With the best teams, supported by the best digital tools, the group intends to continue to grow. SCHOTT AG is owned by the Carl Zeiss Foundation, one of the oldest foundations in Germany. It uses the Group's dividends to promote science. As a foundation company, SCHOTT has anchored responsibility for employees, society and the environment deeply in its DNA. The goal is to become a climate-neutral company by 2030.